RA
ABBV icon

Rise Advisors’s AbbVie ABBV Stock Holding History

Rise Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Sell
1,330
-48
-3% -$10.3K 0.09% 71
2026
Q1 		$296K Buy
1,378
+9
+0.7% +$2K 0.1% 66
2025
Q4 		$313K Sell
1,369
-82
-6% -$18.7K 0.11% 70
2025
Q3 		$336K Buy
1,451
+48
+3% +$9.78K 0.12% 64
2025
Q2 		$260K Buy
1,403
+20
+1% +$3.72K 0.1% 76
2025
Q1 		$290K Buy
1,383
+95
+7% +$18.5K 0.13% 70
2024
Q4 		$229K Buy
1,288
+21
+2% +$3.86K 0.11% 78
2024
Q3 		$250K Buy
1,267
+10
+0.8% +$1.87K 0.12% 75
2024
Q2 		$216K Buy
1,257
+24
+2% +$3.98K 0.11% 87
2024
Q1 		$225K Buy
1,233
+933
+311% +$161K 0.12% 82
2023
Q4 		$46.6K Sell
300
-22
-7% -$3.21K 0.03% 165
2023
Q3 		$47.9K Sell
322
-2,204
-87% -$324K 0.04% 143
2023
Q2 		$340K Sell
2,526
-102
-4% -$15K 0.26% 42
2023
Q1 		$419K Buy
2,628
+6
+0.2% +$917 0.32% 37
2022
Q4 		$424K Buy
2,622
+2
+0.1% +$307 0.34% 37
2022
Q3 		$352K Buy
2,620
+3
+0.1% +$430 0.29% 42
2022
Q2 		$401K Buy
2,617
+61
+2% +$9.32K 0.4% 36
2022
Q1 		$414K Sell
2,556
-233
-8% -$33.8K 0.37% 37
2021
Q4 		$378K Buy
+2,789
New +$329K 0.36% 41

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rise Advisors's ABBV Position: Q2 2026 in Review

Rise Advisors reduced its AbbVie (ABBV) stake by 3.5% in Q2 2026, selling an estimated $10.3K and leaving 1,330 shares worth $335K. The position accounts for 0.09% of the portfolio, ranked #71.

Rise Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $424K in Q4 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Rise Advisors held 1,330 shares of AbbVie worth $335K as of Q2 2026.
  • Rise Advisors sold 48 AbbVie shares in Q2 2026, an estimated $10.3K.
  • AbbVie made up 0.09% of Rise Advisors's portfolio in Q2 2026, its #71 holding.
  • Rise Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • Rise Advisors's AbbVie position peaked at $424K in Q4 2022.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rise Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.